| Literature DB >> 30987215 |
Susan Thapa1, Lori A Fischbach2, Robert Delongchamp3,4, Mohammed F Faramawi5,6, Mohammed Orloff7,8.
Abstract
Gastric cancer is the third leading cause of cancer mortality worldwide. Studies investigating the effect of salt on gastric cancer have mainly used self-reported measures, which are not as accurate as sodium/creatinine ratios because individuals may not know the amount of salt in their food. Using data from a prospective cohort study, we investigated the effect of salt intake on progression to gastric precancerous lesions. Salt intake was estimated by urinary sodium/creatinine ratios, self-reported frequencies of adding salt to food, and total added table salt. We repeated the analyses among groups with and without Helicobacter pylori infection. We did not observe a positive association between salt intake, measured by urinary sodium/creatinine ratio, and overall progression in the gastric precancerous process (adjusted risk ratio (RR): 0.94; 95% confidence interval (CI) 0.76-1.15). We did observe an association between salt intake and increased risk for progression to dysplasia or gastric cancer overall (adjusted risk ratio (RR): 1.32; 95% confidence interval (CI): 0.96-1.81), especially among those who continued to have H. pylori infection at the five-month follow-up (adjusted RR: 1.53; 95% CI: 1.12-2.09), and among those who had persistent H. pylori infection over 12 years (adjusted RR: 1.49; 95% CI: 1.09-2.05). Salt intake may increase the risk of gastric dysplasia or gastric cancer in individuals with H. pylori infection.Entities:
Keywords: atrophic gastritis; dysplasia; gastric cancer; intestinal metaplasia; salt intake
Year: 2019 PMID: 30987215 PMCID: PMC6520970 DOI: 10.3390/cancers11040467
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Baseline characteristics by tertiles of sodium/creatinine ratios.
| Characteristics | Overall | Urinary Sodium/Creatinine Ratio | |||
|---|---|---|---|---|---|
| Tertile 1 | Tertile 2 | Tertile 3 | |||
| Age a | 43.8 (11.5) | 41.7 (11.1) | 42.6 (11.7) | 47.9 (10.8) | |
| Sex (%females) b | 66.1 | 71.7 | 54.6 | 70.2 | |
| Car ownership (%) b | 29.2 | 33.6 | 37.5 | 16.0 | |
| Education (years) a | 6.9 (4.8) | 7.9 (4.7) | 7.1 (5.4) | 5.3 (3.8) | |
| Fruit and vegetable servings per week a | 66.9 (26.3) | 69.4 (28.8) | 69.0 (24.7) | 64.9 (25.6) | |
| Baseline diagnosis (%) b | No gastritis | 2.4 | 6.2 | - | - |
| Non-atrophic gastritis | 31.2 | 38.9 | 26.1 | 26.6 | |
| Atrophic gastritis | 35.3 | 33.6 | 37.5 | 35.1 | |
| Intestinal metaplasia | 28.5 | 20.4 | 34.1 | 33.0 | |
| Dysplasia and gastric cancer | 2.7 | 0.9 | 2.3 | 5.3 | |
a Mean (standard deviation); b percentage of the overall or tertiles of sodium/creatinine ratio.
Risk ratios for the association between salt intake (defined by the average of the baseline and five-month measures of urinary sodium/creatinine ratio) and progression in the gastric precancerous process (11–12 years compared to baseline).
| Outcomes | Overall | Persistent | ||||||
|---|---|---|---|---|---|---|---|---|
| Risk Ratio (CI) | Risk Ratio (CI) | Risk Ratio (CI) | Risk Ratio (CI) | |||||
| Overall progression in the gastric precancerous process | 85:175 | 0.94 (0.76–1.15) | 72:144 | 0.95 (0.76–1.19) | 13:31 | 0.80 (0.43–1.48) | 64:121 | 0.96 (0.77–1.20) |
| Incident progression to atrophic gastritis | 28:45 | 1.21 (0.93–1.57) | 23:37 | 1.13 (0.85–1.51) | 5:8 | 1.92 (0.67–5.48) | 20:29 | 1.07 (0.77–1.49) |
| Incident progression to intestinal metaplasia | 63:112 | 0.89 (0.71–1.11) | 56:89 | 0.91 (0.73–1.15) | 7:23 | 0.81 (0.31–2.16) | 51:73 | 0.97 (0.78–1.20) |
| Incident progression to dysplasia or gastric cancer | 10:243 | 1.32 (0.96–1.81) | 8:203 | 1.53 (1.12–2.09) | 2:40 | b | 8:172 | 1.49 (1.09–2.05) |
a Adjusted for age, gender, car ownership, and fruit and vegetable intake. b Missing risk ratio due to sparse data. c Total at risk overall is less than the sum of the total at risk for each specific histological diagnosis since participants can be at risk for more than one outcome at baseline. CI: confidence interval, H. pylori: Helicobacter pylori